


Evidencia sobre el Uso de Quetiapina en los Trastornos Bipolares

Jorge M Tamayo, M.D., B.Sc.(Pharm.)

Departamento de Psiquiatría - Universidad CES
Departamento de Psicología - U.P.B.
Programa de Psicología - U. Eafit

Patrones de la Enfermedad en 258 Pacientes Bipolares (1 Año de Seguimiento)



Group I: > 3/4 Year Ill (26.4%)







A pesar del tratamiento farmacológico, 26.4% de los pacientes permanecían afectados la mayor parte del tiempo y 40.7% de manera intermitente. Además, 62.8% presentaban más de 4 episodios por año. La depresión fue 3 veces más predominante que la manía (33.2% del año)

Post RM et al. J Clin Psychiatry 2003;64:680-690

PFOL@2019







Eutimizantes en Manía Aguda. Meta-Análisis de Red (n=14256)

Risperidona	0.81 [0.48 to 1.37]	1.28 [0.78 to 2.1]	0.57 [0.29 to 1.14]	0.63 [0.37 to 1.08]	0.67 [0.37 to 1.37]	1 [0.48 to 2.11]	0.88 [0.56 to 1.54]	0.69 [0.34 to 1.36]	0.95 [0.52 to 1.76]	—	0.94 [0.63 to 1.44]	0.89 [0.53 to 1.56]	0.17 [0.02 to 1.1]	0.51 [0.24 to 1.08]	0.47 [0.17 to 1.24]	0.58 [0.28 to 1.04]
Haloperidol	0.11 [-0.19 to 0.36]	0.88 [0.56 to 1.21]	0.71 [0.39 to 1.31]	0.78 [0.53 to 1.21]	0.83 [0.42 to 1.58]	1.24 [0.64 to 2.45]	1.09 [0.72 to 1.66]	0.84 [0.45 to 1.38]	1.19 [0.71 to 1.88]	—	1.04 [0.59 to 1.59]	1.1 [0.68 to 1.78]	0.21 [0.02 to 1.38]	0.63 [0.29 to 1.28]	0.58 [0.29 to 1.47]	0.74 [0.39 to 1.04]
Olanzapina	0.17 [-0.06 to 0.36]	0.06 [-0.14 to 0.25]	0.21 [-0.25 to 0.81]	0.45 [0.23 to 0.73]	0.53 [0.28 to 0.97]	0.78 [0.41 to 1.15]	1.24 [0.64 to 2.07]	0.69 [0.35 to 1.07]	0.74 [0.42 to 1.23]	—	0.65 [0.27 to 1.17]	0.69 [0.47 to 1.29]	0.17 [-0.02 to 0.33]	0.58 [0.21 to 0.95]	0.52 [0.21 to 0.83]	0.64 [0.29 to 0.92]
Cariprazina	0.18 [-0.16 to 0.5]	0.07 [-0.24 to 0.36]	0.21 [-0.17 to 0.25]	0.33 [-0.29 to 0.31]	0.02 [-0.29 to 0.31]	1.1 [0.61 to 1.99]	1.17 [0.56 to 2.47]	1.24 [0.81 to 3.81]	1.03 [0.56 to 2.51]	1.86 [0.87 to 3.23]	—	1.46 [0.71 to 2.96]	1.25 [0.83 to 2.88]	0.3 [0.04 to 0.56]	0.2 [0.1 to 0.27]	0.32 [0.13 to 0.75]
Litio	0.2 [-0.06 to 0.44]	0.08 [-0.13 to 0.29]	0.23 [-0.17 to 0.25]	0.02 [-0.29 to 0.31]	0.02 [-0.29 to 0.31]	1.06 [0.57 to 1.96]	1.88 [0.83 to 3.06]	1.39 [0.93 to 2.17]	1.01 [0.58 to 2.01]	1.51 [0.84 to 2.45]	—	1.33 [0.73 to 2.36]	1.4 [0.93 to 2.2]	0.27 [0.04 to 0.48]	0.81 [0.45 to 1.43]	0.74 [0.39 to 1.29]
Carbamazepina	0.21 [-0.13 to 0.56]	0.1 [-0.21 to 0.42]	0.04 [-0.26 to 0.36]	0.03 [-0.33 to 0.42]	0.02 [-0.29 to 0.34]	0.02 [-0.29 to 0.34]	1.49 [0.82 to 3.41]	1.21 [0.68 to 2.54]	1.01 [0.46 to 2.29]	1.41 [0.73 to 2.87]	—	1.24 [0.59 to 2.67]	1.22 [0.81 to 2.53]	0.26 [0.03 to 0.48]	0.75 [0.29 to 1.27]	0.89 [0.29 to 1.56]
Paliperidona	0.28 [-0.09 to 0.63]	0.17 [-0.17 to 0.46]	0.11 [-0.22 to 0.42]	0.1 [-0.28 to 0.49]	0.08 [-0.24 to 0.41]	0.07 [-0.35 to 0.46]	0.07 [-0.35 to 0.46]	0 [-0.35 to 0.46]	0.88 [0.44 to 1.72]	0.88 [0.31 to 1.51]	—	0.94 [0.38 to 1.8]	0.89 [0.44 to 1.75]	0.17 [0.02 to 1.13]	0.21 [0.22 to 1.18]	0.47 [0.16 to 1.32]
Aripirazole	0.27 [0.14 to 0.54]	0.17 [-0.08 to 0.37]	0.11 [-0.11 to 0.33]	0.1 [-0.21 to 0.41]	0.08 [-0.14 to 0.31]	0.06 [-0.27 to 0.38]	0 [-0.34 to 0.34]	0 [-0.34 to 0.34]	0.77 [0.4 to 1.48]	0.88 [0.61 to 1.36]	—	0.95 [0.52 to 1.74]	1.01 [0.61 to 1.64]	0.2 [0.03 to 1.27]	0.28 [0.5 to 1.16]	0.33 [0.21 to 1.36]
Asenapina	0.29 [-0.02 to 0.62]	0.18 [-0.13 to 0.46]	0.13 [-0.19 to 0.39]	0.12 [-0.26 to 0.49]	0.09 [-0.21 to 0.41]	0.08 [-0.32 to 0.46]	0.01 [-0.36 to 0.42]	0.02 [-0.36 to 0.42]	0.87 [0.31 to 1.51]	1.4 [0.71 to 2.8]	—	1.23 [0.58 to 2.41]	1.31 [0.89 to 2.44]	0.25 [0.03 to 0.48]	0.76 [0.24 to 1.71]	0.89 [0.25 to 1.53]
Quetiapina	0.3 [0.19 to 0.6]	0.19 [-0.13 to 0.42]	0.13 [-0.12 to 0.37]	0.12 [-0.2 to 0.45]	0.1 [-0.14 to 0.38]	0.09 [-0.27 to 0.42]	0.02 [-0.32 to 0.42]	0.01 [-0.34 to 0.34]	0.88 [0.29 to 1.51]	0.95 [0.42 to 1.81]	—	0.88 [0.46 to 1.47]	0.83 [0.33 to 1.59]	0.18 [0.02 to 1.14]	0.24 [0.26 to 1.1]	0.49 [0.16 to 1.28]
Oxcarbazepina	0.31 [-0.02 to 0.63]	0.21 [-0.08 to 0.48]	0.13 [-0.14 to 0.43]	0.12 [-0.22 to 0.5]	0.14 [-0.17 to 0.42]	0.12 [-0.22 to 0.42]	0.1 [-0.28 to 0.47]	0.1 [-0.36 to 0.42]	0.02 [-0.32 to 0.42]	0.02 [-0.32 to 0.42]	—	—	—	—	—	—
Ziprasidona	0.31 [-0.02 to 0.63]	0.21 [-0.08 to 0.48]	0.13 [-0.14 to 0.43]	0.12 [-0.22 to 0.5]	0.14 [-0.17 to 0.42]	0.12 [-0.22 to 0.42]	0.1 [-0.28 to 0.47]	0.1 [-0.36 to 0.42]	0.02 [-0.32 to 0.42]	0.02 [-0.32 to 0.42]	—	0.98 [0.57 to 1.58]	1.04 [0.63 to 1.51]	0.21 [0.03 to 1.23]	0.81 [0.28 to 1.35]	0.71 [0.21 to 1.52]
Valproato	0.33 [0.26 to 0.55]	0.22 [-0.02 to 0.43]	0.18 [-0.14 to 0.34]	0.15 [-0.16 to 0.45]	0.13 [-0.09 to 0.34]	0.12 [-0.22 to 0.42]	0.12 [-0.29 to 0.38]	0.05 [-0.29 to 0.34]	0.04 [-0.24 to 0.29]	0.03 [-0.24 to 0.29]	—	0.91 [-0.3 to 0.31]	0.91 [-0.3 to 0.31]	0.19 [0.03 to 1.21]	0.28 [0.15 to 1.46]	0.33 [0.21 to 0.97]
Vandimetina	0.34 [0.14 to 0.87]	0.26 [0.06 to 0.77]	0.18 [0.02 to 0.66]	0.15 [0.02 to 0.5]	0.13 [0.02 to 0.47]	0.12 [0.02 to 0.42]	0.05 [-0.29 to 0.38]	0.04 [-0.29 to 0.34]	0.03 [-0.24 to 0.29]	0.03 [-0.24 to 0.29]	—	0.91 [-0.61 to 1.46]	0.91 [-0.61 to 1.46]	0.19 [-0.15 to 0.85]	0.28 [-0.48 to 0.98]	0.33 [0.21 to 0.97]
Lamotrigina	0.34 [0.14 to 0.87]	0.26 [0.06 to 0.77]	0.18 [0.02 to 0.66]	0.15 [0.02 to 0.5]	0.13 [0.02 to 0.47]	0.12 [0.02 to 0.42]	0.05 [-0.29 to 0.38]	0.04 [-0.29 to 0.34]	0.03 [-0.24 to 0.29]	0.03 [-0.24 to 0.29]	—	0.91 [-0.61 to 1.46]	0.91 [-0.61 to 1.46]	0.19 [-0.15 to 0.85]	0.28 [-0.48 to 0.98]	0.33 [0.21 to 0.97]
Litio	0.34 [0.14 to 0.87]	0.26 [0.06 to 0.77]	0.18 [0.02 to 0.66]	0.15 [0.02 to 0.5]	0.13 [0.02 to 0.47]	0.12 [0.02 to 0.42]	0.05 [-0.29 to 0.38]	0.04 [-0.29 to 0.34]	0.03 [-0.24 to 0.29]	0.03 [-0.24 to 0.29]	—	0.91 [-0.61 to 1.46]	0.91 [-0.61 to 1.46]	0.19 [-0.15 to 0.85]	0.28 [-0.48 to 0.98]	0.33 [0.21 to 0.97]
Licarbazepina	0.34 [0.14 to 0.87]	0.26 [0.06 to 0.77]	0.18 [0.02 to 0.66]	0.15 [0.02 to 0.5]	0.13 [0.02 to 0.47]	0.12 [0.02 to 0.42]	0.05 [-0.29 to 0.38]	0.04 [-0.29 to 0.34]	0.03 [-0.24 to 0.29]	0.03 [-0.24 to 0.29]	—	0.91 [-0.61 to 1.46]	0.91 [-0.61 to 1.46]	0.19 [-0.15 to 0.85]	0.28 [-0.48 to 0.98]	0.33 [0.21 to 0.97]
Placebo	0.34 [0.14 to 0.87]	0.26 [0.06 to 0.77]	0.18 [0.02 to 0.66]	0.15 [0.02 to 0.5]	0.13 [0.02 to 0.47]	0.12 [0.02 to 0.42]	0.05 [-0.29 to 0.38]	0.04 [-0.29 to 0.34]	0.03 [-0.24 to 0.29]	0.03 [-0.24 to 0.29]	—	0.91 [-0.61 to 1.46]	0.91 [-0.61 to 1.46]	0.19 [-0.15 to 0.85]	0.28 [-0.48 to 0.98]	0.33 [0.21 to 0.97]

Eficacia (crema) y discontinuación por cualquier causa (azul)

Yildiz A et al. Psychological Medicine 2015; 45:299-317

PROL©2019

Eutimizantes en Manía Aguda. Meta-Análisis

Drug	Trials	Subjects	Mean Dose (mg/day)	Response (RR [95% CI])	Dropout (RR [95% CI])
Risperidone	4	976	3.50 ± 0.00	2.66 [1.86–3.81]	0.60 [0.38–0.93]
Carbamazepine	2	427	700 ± 80.0	2.64 [1.60–4.30]	0.88 [0.51–1.56] ^a X
Haloperidol	9	1663	9.45 ± 5.65	2.47 [1.89–3.25]	0.74 [0.53–1.04] ^a X
Cariprazina	4	1198	7.12 ± 1.89	2.33 [1.56–3.53]	1.04 [0.63–1.73] ^a X
Olanzapina	10	2031	13.4 ± 1.92	2.33 [1.82–3.02]	0.47 [0.35–0.63]
Aripirazole	8	1982	22.5 ± 4.74	2.07 [1.56–2.77]	0.68 [0.48–0.96]
Quetiapina	6	1306	612 ± 118	2.05 [1.49–2.85]	0.63 [0.41–0.94]
Valproate	7	1299	1431 ± 954	2.05 [1.48–2.87]	0.67 [0.47–0.97]
Litio	14	1981	1260 ± 251	1.92 [1.49–2.49]	0.94 [0.69–1.29] ^a X
Paliperidone	5	1157	7.50 ± 3.87	1.72 [1.08–2.74]	0.60 [0.33–1.06] ^a X
Asenapina	4	841	18.3 ± 0.14	1.61 [1.03–2.54]	0.88 [0.51–1.53] ^a X
Ziprasidone	4	839	124 ± 7.21	1.47 [1.06–2.04]	0.93 [0.61–1.41] ^a X

a Abandono por cualquier causa es mayor que con placebo para asenapina, carbamazepina, cariprazina, haloperidol, litio, paliperidona y ziprasidona

Baldessarini RJ et al. Mol Psychiatry 2019;24:198-217

PROL©2019


Meta-análisis sobre el Uso de la Monoterapia de Eutimizantes en Depresión Bipolar - Respuesta

Treatments (trials)	Subjects (n)	Dropout (%) Drug/Placebo	Responders/Subjects		RR [95%CI]
			Drug (%)	Placebo (%)	
Lithium					
Lithium [Li] (1)	265	25.0/27.8	85/136 (62.5)	72/129 (55.8)	1.12 [0.92–1.37]* X
Anticonvulsants					
Carbamazepine [CBZ] (1)	70	26.5/40.0	30/47 (63.8)	8/23 (34.8)	1.84 [1.01–3.34]
Lamotrigine [LTG] (5)	1071	34.8/33.6	255/541 (47.1)	160/530 (30.2)	1.56 [1.33–1.83]
Valproate [VPA] (4)	140	41.1/47.9	28/69 (40.6)	13/71 (18.3)	2.22 [1.26–3.91]
Anticonvulsants (10)	1281	34.1/40.5	313/657 (47.6)	181/624 (29.0)	1.61 [1.39–1.87]
Antipsychotics					
Aripiprazole [APZ] (2)	690	44.0/32.4	148/337 (43.9)	147/353 (41.6)	1.10 [0.81–1.48]* X
Cariprazine [CAR] (1)	236	29.1/28.0	86/191 (44.4)	14/45 (31.1)	1.81 [0.91–3.62]*
Lurasidone [LUR] (1)	485	–	168/323 (52.0)	49/162 (30.2)	2.50 [1.68–3.73]
Olanzapine [ONZ] (2)	1220	36.9/45.0	317/694 (45.7)	185/526 (35.2)	1.55 [1.23–1.96]
Quetiapine [QTP] (5)	2485	34.4/35.1	1135/1760 (64.5)	322/725 (44.4)	2.27 [1.91–2.71]
Ziprasidone [ZPS] (2)	928	38.8/31.9	281/554 (50.7)	187/374 (50.0)	1.03 [0.79–1.34]* X
Antipsychotics (13)	6044	36.6/35.1	2135/3859 (55.3)	904/2185 (41.4)	1.28 [1.09–1.51]
Pooled/totals (24)	7590	35.7/39.9	2533/4652 (54.4)	1157/2938 (39.4)	1.34 [1.17–1.53]



Baldessarini RJ et al. Mol Psychiatry 2019;24:198-217



PROL©2019


Meta-análisis – Manía Emergente a Tratamiento con Quetiapina en Pacientes con Trastorno Bipolar



Suttajit S et al. Drug Des Devel Ther 2014;8:827-38







Parkinsonismo con Antipsicóticos: Esquizo. Vs. TB

Antipsicótico (mg/d)		SEP	ARR o ARI, %
Esquizofrenia			
Haloperidol 8–12 (n = 222)	PBO (n = 228)	-21.3 (-29.3 a -13.0)	-5 (-8 a -3)*
Aripiprazol 15–20 (n = 203)	PBO (n = 207)	-1.2 (-7.4 a 5.0)	-84 (20 a -13)
Quetiapina 600 (n = 51)	PBO (n = 51)	9.8 (-3.6 a 23.3)	10 (4 a -28)
Risperidona 6 (n = 185)	PBO (n = 191)	-0.7 (-5.9 a 4.3)	-137 (23 a -17)
Ziprasidona 120–160 (n = 151)	PBO (n = 140)	-5.2 (-10.4 a -0.5)	-19 (-203 a -10)*
Trastorno Bipolar (Manía)			
Haloperidol 2–8 (n = 243)	PBO (n = 241)	-30.8 (-37.6 a -23.8)	-3 (-4 a -3)*
Quetiapina 600 (n = 209)	PBO (n = 198)	0.2 (-6.4 a 6.9)	470 (15 a -16)
Risperidona 4.1–5.6 (n = 300)	PBO (n = 284)	-18.3 (-24.1 a -12.4)	-5 (-8 a -4)*
Ziprasidona 112–147 (n = 139)	PBO (n = 66)	-9.3 (-15.7 a -1.5)	-11 (-67 a -6)*

* p<0.05; ARI = absolute risk increase; ARR = absolute risk reduction

Gao K et al. J Clin Psychopharmacol 2008;28:203–209

PFOL©2019

Current Psychiatry Reviews, 2013, 9, 41-50

Therapy of No-Type I Bipolar Spectrum Disorders: A Systematic Review


Jorge M. Tamayo^{1-3,*}, David Mejía-Rodríguez³, Ana M. Navarro-Montoya³,
Lina M. Álvarez-Arboleda², Gustavo Vázquez^{4,5} and Eduard Vieta⁶

¹Department of Psychiatry, CES University, Medellín, Colombia; ²Research Group on Emotion, Cognition, and Behavior (ECCO), Department of Psychology, Universidad Pontificia Bolivariana, Medellín, Colombia; ³HypoMed Project, Mental Health Research Center (CESISM), CES University, Medellín, Colombia; ⁴Department of Neuroscience, University of Palermo, Buenos Aires, Argentina; ⁵International Consortium for Bipolar Disorders Research, Department of Psychiatry & Neuroscience Program, Harvard Medical School, Boston, McLean Division of Massachusetts General Hospital, Belmont, MA, USA; ⁶Bipolar Disorders Program, Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain

La mayoría de los estudios identificados adolecen de limitaciones metodológicas, o son observacionales o retrospectivos.

Sin embargo, los estabilizadores de ánimo y algunas formas de psicoterapia pueden ser útiles en los pacientes con TBN-I

PROL©2019




Características del Trastorno Bipolar Tipo II

- El TB tipo II fue descrito por Dunner et al. en 1976.
- Consiste en episodios hipomaniacos, en ausencia de manías, más episodios depresivos mayores
- Prevalencia: 0.5 a 6.4% en población general.
- Mayor cronicidad que el TB tipo I. Con mayor número de episodios depresivos [39 veces más que hipomanía (50.3% vs 1.3%)] y mayor suicidalidad.
- Tiende a tener alta estabilidad diagnóstica. En un período de 10 años sólo el 7.2% experimentan un episodio maniaco.

Yatham LN & Kesavan M. In: The Treatment of Bipolar Disorder . Chapter 9. Oxford University Press, 2017

PFOL©2019

Quetiapina XR Vs. Placebo en Depresión Bipolar Tipo II (Análisis Combinado de los Estudios BOLDER y EMBOLDEN)



***p < 0.001 vs placebo

Young AH, et al. Int J Bipolar Disord 2013;1:10

PFOL©2019

